Photodynamic therapy in oral cancer: a review of clinical studies

Medical Oncology, Journal Year: 2023, Volume and Issue: 40(3)

Published: Feb. 7, 2023

Language: Английский

---

A NIR‐II Fluorescent PolyBodipy Delivering Cationic Pt‐NHC with Type II Immunogenic Cell Death for Combined Chemotherapy and Photodynamic Immunotherapy

Advanced Functional Materials, Journal Year: 2023, Volume and Issue: 33(29)

Published: April 21, 2023

Abstract Tumor immunotherapy has emerged as one of the most promising clinical techniques to treat cancer tumors. Despite its application, cancerous immunosuppressive microenvironment limits therapeutic efficiency treatment. To generate a stronger immunogenic effect, herein, platinum complex for chemotherapy and BODIPY photosensitizer photodynamic therapy are encapsulated into multimodal type II cell death (ICD) induce nanoparticles. As able ICD, an exceptionally strong immune response is observed in triple‐negative breast cells. While remaining stable therefore poorly cytotoxic dark, nanomaterial found quickly dissociate upon exposure near‐infrared light, causing mechanism action cells well multicellular tumor spheroids through combined chemotherapy, therapy, immunotherapy. The nanoparticles nearly fully eradicate strongly enhance survival tumor‐bearing mice models using low drug light doses.

Language: Английский

---

Dendritic Cell Vaccines: A Shift from Conventional Approach to New Generations

Cells, Journal Year: 2023, Volume and Issue: 12(17), P. 2147 - 2147

Published: Aug. 25, 2023

In the emerging era of cancer immunotherapy, immune checkpoint blockades (ICBs) and adoptive cell transfer therapies (ACTs) have gained significant attention. However, their therapeutic efficacies are limited due to presence cold type tumors, immunosuppressive tumor microenvironment, immune-related side effects. On other hand, dendritic (DC)-based vaccines been suggested as a new immunotherapy regimen that can address limitations encountered by ICBs ACTs. Despite success first generation DC-based vaccines, represented FDA-approved vaccine Provenge, several challenges remain unsolved. Therefore, DC strategies actively investigated. This review addresses currently most adopted classical evaluates generations in detail, including biomaterial-based, immunogenic death-inducing, mRNA-pulsed, small extracellular vesicle (sEV)-based, sEV-based vaccines. These innovative envisioned provide breakthrough landscape expected be supported further preclinical clinical studies.

Language: Английский

---

Targeting inflammation as cancer therapy

Journal of Hematology & Oncology, Journal Year: 2024, Volume and Issue: 17(1)

Published: March 22, 2024

Abstract Inflammation has accompanied human beings since the emergence of wounds and infections. In past decades, numerous efforts have been undertaken to explore potential role inflammation in cancer, from tumor development, invasion, metastasis resistance tumors treatment. Inflammation-targeted agents not only demonstrate suppress cancer but also improve efficacy other therapeutic modalities. this review, we describe highly dynamic complex inflammatory microenvironment, with discussion on key mediators including cells, cytokines, their downstream intracellular pathways. addition, especially address development highlight action mechanisms inflammation-targeted therapies antitumor response. Finally, summarize results both preclinical clinical studies up date illustrate translation therapies.

Language: Английский

---

Nanoplatform-enhanced photodynamic therapy for the induction of immunogenic cell death

Journal of Controlled Release, Journal Year: 2024, Volume and Issue: 365, P. 1058 - 1073

Published: Jan. 1, 2024

Language: Английский

---